Angiopoietin-2 TIEs up macrophages in tumor angiogenesis

Michele De Palma, Luigi Naldini

Research output: Contribution to journalArticle

Abstract

Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.

Original languageEnglish
Pages (from-to)5226-5232
Number of pages7
JournalClinical Cancer Research
Volume17
Issue number16
DOIs
Publication statusPublished - Aug 15 2011

Fingerprint

Angiopoietin-2
Macrophages
Neoplasms
Islets of Langerhans
Blood Vessels
Cell Biology
Adenocarcinoma
Breast
Endothelial Cells
Monoclonal Antibodies
Ligands

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. / De Palma, Michele; Naldini, Luigi.

In: Clinical Cancer Research, Vol. 17, No. 16, 15.08.2011, p. 5226-5232.

Research output: Contribution to journalArticle

De Palma, Michele ; Naldini, Luigi. / Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 16. pp. 5226-5232.
@article{ebc4f352d69c4e30b06c1f3b2e253a09,
title = "Angiopoietin-2 TIEs up macrophages in tumor angiogenesis",
abstract = "Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.",
author = "{De Palma}, Michele and Luigi Naldini",
year = "2011",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-10-0171",
language = "English",
volume = "17",
pages = "5226--5232",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Angiopoietin-2 TIEs up macrophages in tumor angiogenesis

AU - De Palma, Michele

AU - Naldini, Luigi

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.

AB - Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.

UR - http://www.scopus.com/inward/record.url?scp=79960638881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960638881&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-0171

DO - 10.1158/1078-0432.CCR-10-0171

M3 - Article

C2 - 21576085

AN - SCOPUS:79960638881

VL - 17

SP - 5226

EP - 5232

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -